127. 前頭側頭葉変性症 Frontotemporal lobar degeneration Clinical trials / Disease details


臨床試験数 : 89 薬物数 : 104 - (DrugBank : 33) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 117

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03625128
(ClinicalTrials.gov)
January 2, 201812/7/201818F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsPhase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal ControlsAlzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive ImpairmentDrug: F-18Chang Gung Memorial HospitalNULLCompleted20 Years90 YearsAll36Early Phase 1Taiwan
2EUCTR2017-000094-36-SE
(EUCTR)
31/03/201730/01/2017The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disordersThe BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment.
MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-RO6958948
Trade Name: Vizamyl (flutemetamol(F-18))
Product Name: Vizamyl
Skåne University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Sweden
3NCT01623284
(ClinicalTrials.gov)
March 20107/6/2012PiB PET Scanning in Speech and Language Based DementiasPiB PET Scanning in Speech and Language Based DementiasPPA;Primary Progressive Aphasia;Aphasia;Non-fluent Aphasia;Semantic Dementia;Apraxia of Speech;Primary Progressive Nonfluent Aphasia;Progressive AphasiaDrug: C-11 PiB;Drug: F-18 FDGMayo ClinicNULLCompleted18 YearsN/ABoth168Phase 1United States
4NCT00950430
(ClinicalTrials.gov)
April 200829/7/2009Imaging of Brain Amyloid Plaques in the Aging PopulationBrain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and DementiaAlzheimer's Disease;Dementia With Lewy Bodies;Frontotemporal Dementia;Vascular DementiaDrug: Pittsburgh Compound B (C-11 PiB);Drug: F-18 FDG;Drug: Tau (18-F-AV-1451)Mayo ClinicNational Institute on Aging (NIA)Enrolling by invitation30 Years100 YearsAll5000Phase 4United States